Cardiovascular Tests: Use & Limits of Biochemical Markers - Therapeutic Measurements of ADMA Involved in Cardiovascular Disorders
Authors: Smith, Caroline L.1; Vallance, Patrick1
Source: Current Pharmaceutical Design, Volume 11, Number 17, July 2005 , pp. 2177-2185(9)
Publisher: Bentham Science Publishers
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Asymmetric dimethylarginine (ADMA) is an endogenously occurring methylarginine that inhibits nitric oxide synthesis. Plasma levels of methylarginines increase in renal failure and certain cardiovascular pathologies, and in patients with end stage renal failure the level of ADMA predicts the risk of cardiovascular events and overall mortality. The object of this review is to describe the mechanisms of ADMA synthesis, metabolism and uptake and to outline techniques for measuring ADMA and the pathological states in which ADMA levels are altered.Keywords: nitric oxide (no); nitric oxide synthases (nos); nadph; protein arginine methyltransferases (prmt); single nucleotide polymorphisms (snp); angiogenesis; arginine; cardiovascular disorders; pre-eclampsia
Document Type: Review article
DOI: 10.2174/1381612054367364
Affiliations: 1: Centre for Clinical Pharmacology and Therapeutics, British Heart Foundation Laboratories, Department of Medicine, University College London, 5, University Street, London. WC1E 6JJ.
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help